Biotech industry tries to recover from 2-year lull

Brower, Vicki
March 2003
JNCI: Journal of the National Cancer Institute;3/5/2003, Vol. 95 Issue 5, p348
Academic Journal
journal article
Looks at the financial performance of the biotechnology industry in the U.S. Role of the corporate side of biotechnology firms in the downward turn of the industry; Advantage of biotechnology drugs over technology products in terms of long-term investment; Effect of cancer drug approval on biotechnology industry.


Related Articles

  • Record integrity and licensing your intellectual property. Avellanet, John // Journal of Commercial Biotechnology;Jan2009, Vol. 15 Issue 1, p16 

    For the biotechnology executive looking to cut a deal with a pharmaceutical company, it is not the type of new molecule that matters, but the quality of the records and data that back up the new biotechnology drug's efficacy that matters. Executives unprepared for pharma's due diligence weaken...

  • Product Preview.  // Urology Times;8/15/2006, Vol. 34 Issue 10, p35 

    The article presents news briefs concerning pharmaceutical product developments. The immunotherapy agent TroVax for advanced renal cell carcinoma developed by Oxford BioMedica has received a special protocol assessment agreement for a phase III trial from the U.S. Food and Drug Administration....

  • Biotech investment offers promise, pitfalls. JORDAN, CHRISTOPHER P. // Fairfield County Business Journal;2/15/2016, Vol. 52 Issue 7, p15 

    The article focuses on the benefits and opportunities offered by investing in the biotechnology industry despite reports from the NASDAQ Biotech Index on the decline in the industry in January 2016. It discusses the research conducted by The Independent Institute which found that only eight...

  • Proteolix's myeloma drug receivesFDA orphan designation.  // PharmaWatch: Biotechnology;May2008, Vol. 7 Issue 5, p11 

    The article reports on the orphan drug designation granted by the U.S. Food and Drug Administration (FDA) to Proteolix Inc.'s carfilzomib, a selective blocker of proteasome activity for the treatment of multiple myeloma. The orphan drug act provides the drug developer with several financial...

  • News in brief. DeFrancesco, Laura; Jayaraman, K. S.; Katsnelson, Alla; Ratner, Mark; Rothwell, Victoria; Shaffer, Catherine; Sheridan, Cormac; Waltz, Emily // Nature Biotechnology;Jul2007, Vol. 25 Issue 7, p703 

    The article offers news briefs related to biotechnology industry. The U.S. Food and Drug Administration (FDA) has turned down the application for approval of Provenge, a vaccine used for treating prostate cancer, from firm Dendreon. The National Health Service (NHS) and drug manufacturer...

  • CLINIC ROUNDUP.  // BioWorld Today;8/17/2009, Vol. 20 Issue 157, p4 

    This section offers news briefs on the biotechnology industry. Oxygen Biotherapeutics Inc. has received approval to start its Phase II, dose-escalation trial in Switzerland covering the use of Oxycyte in traumatic brain injury. DNage's investigational new drug application for Prodarsan has been...

  • Breakthrough Drugs Raise Development and Production Challenges. Wechsler, Jill // BioPharm International;Jul2015, Vol. 28 Issue 7, p8 

    The article discusses how breakthrough drugs program raise development and production challenges. Topics discussed include establishment of breakthrough program as part of the U.S. Food and Drug Administration (FDA) Safety and Innovation Act of 2012, safety issues related to new drug...

  • suzhou PHARMA SERVICES.  // Contract Pharma;2013 Corporate Capabilities & Contract Services Directory, p212 

    The article focuses on Lyndhurst, New Jersey-based pharmaceutical company Suzhou Pharma Services. It mentions that Suzhou is a contract and manufacturing organization working with U.S. Food and Drug Administration (FDA) and Chinese government-approved drugs. It adds that the company provides...

  • When will the bear move on? Brower, Vicki // EMBO Reports;Nov2002, Vol. 3 Issue 11, p1015 

    This article reports on problems faced by biotechnology industry in the U.S. in 2002. The year 2002 has not been kind to biotechnology: the industry has lost nearly half its value since January. Recent rejections of new drug applications from various bio-technology companies by the U.S. Food and...

  • Oncology market: Cytotoxics face biotech challenge.  // PharmaWatch: Cancer;April 2003, Vol. 2 Issue 4, p22 

    Reports that the oncology market has been dominated by cytotoxic treatments. Sales performance of Gleevec from Novartis AG; Recommendation of Bexxar from Corixa Corp. and GlaxoSmithKline PLC for approval by the U.S. Food and Drug Administration; Need of biotechnology companies for licensing...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics